WO1995005452A3 - Compositions et procedes ameliores pour l'administration de molecuiles a activite biologique a l'aide de cellules modifiees genetiquement comprises dans des capsules biocompatibles immuno-isolatrices - Google Patents

Compositions et procedes ameliores pour l'administration de molecuiles a activite biologique a l'aide de cellules modifiees genetiquement comprises dans des capsules biocompatibles immuno-isolatrices Download PDF

Info

Publication number
WO1995005452A3
WO1995005452A3 PCT/US1994/009299 US9409299W WO9505452A3 WO 1995005452 A3 WO1995005452 A3 WO 1995005452A3 US 9409299 W US9409299 W US 9409299W WO 9505452 A3 WO9505452 A3 WO 9505452A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
methods
active molecules
delivery
biocompatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/009299
Other languages
English (en)
Other versions
WO1995005452A2 (fr
Inventor
E Edward Baetge
Joseph P Hammang
Frank T Gentile
Mark D Lindner
Shelley R Winn
Dwaine F Emerich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbot Medical Inc
Original Assignee
Cytotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU75680/94A priority Critical patent/AU7568094A/en
Priority to FI960611A priority patent/FI960611A7/fi
Priority to AT94925921T priority patent/ATE218893T1/de
Priority to EP94925921A priority patent/EP0802800B1/fr
Priority to DK94925921T priority patent/DK0802800T3/da
Priority to JP50422895A priority patent/JP4098355B2/ja
Priority to CA2169292A priority patent/CA2169292C/fr
Application filed by Cytotherapeutics Inc filed Critical Cytotherapeutics Inc
Priority to DE69430824T priority patent/DE69430824T2/de
Publication of WO1995005452A2 publication Critical patent/WO1995005452A2/fr
Publication of WO1995005452A3 publication Critical patent/WO1995005452A3/fr
Priority to US08/450,862 priority patent/US5908623A/en
Priority to NO960547A priority patent/NO960547L/no
Anticipated expiration legal-status Critical
Priority to US09/236,246 priority patent/US6264941B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)

Abstract

Dispositifs et procédés améliorés pour l'expression stable et prolongée d'une molécule à activité biologique à l'aide d'une capsule biocompatible renfermant des cellules manipulées génétiquement et servant à administrer efficacement des molécules à activité biologique assurant ou améliorant une fonction biologique au sein d'un hôte mammifère. Ces nouvelles capsules sont biocompatibles et récupérables sans difficultés. Plus spécialement, on a prévu des compositions et procédés améliorés mettant en ÷uvre des cellules dotées par transfection de molécules d'ADN recombiné comportant des séquences d'ADN qui codent pour des molécules à activité biologique associées activement à des promoteurs non susceptibles de subir une rétrorégulation in vivo lors de leur implantation dans un hôte mammifère. Par ailleurs, ces procédés permettent l'administration stable, efficace et prolongée dans certains sites au sein d'un mammifère déterminé de molécules à activité biologique en provenance de cellules vivantes. On a également prévu un système général d'entretien pendant des durées prolongées de l'expression in vivo de transgènes.
PCT/US1994/009299 1993-08-12 1994-08-12 Compositions et procedes ameliores pour l'administration de molecuiles a activite biologique a l'aide de cellules modifiees genetiquement comprises dans des capsules biocompatibles immuno-isolatrices Ceased WO1995005452A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP50422895A JP4098355B2 (ja) 1993-08-12 1994-08-12 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
FI960611A FI960611A7 (fi) 1993-08-12 1994-08-12 Bioyhteensopivia, immunologisesti eristettyjä kapseleita, jotka sisält ävät geneettisesti muunneltuja soluja
AT94925921T ATE218893T1 (de) 1993-08-12 1994-08-12 Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
EP94925921A EP0802800B1 (fr) 1993-08-12 1994-08-12 Capsules biocompatibles immuno-isolatrices comprennant des cellules modifiees genetiquement pour l'administration de molecules a activite biologique
DK94925921T DK0802800T3 (da) 1993-08-12 1994-08-12 Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler
CA2169292A CA2169292C (fr) 1993-08-12 1994-08-12 Compositions et methodes ameliorees de liberation de molecules biologiquement actives au moyen de cellules genetiquement modifiees contenues dans des capsules d'immunoisolation biocompatibles
DE69430824T DE69430824T2 (de) 1993-08-12 1994-08-12 Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
AU75680/94A AU7568094A (en) 1993-08-12 1994-08-12 Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US08/450,862 US5908623A (en) 1993-08-12 1995-05-25 Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
NO960547A NO960547L (no) 1993-08-12 1996-02-12 Biokompatible immunoisolatoriske kapsler inneholdende genetisk endrede celler
US09/236,246 US6264941B1 (en) 1993-08-12 1999-01-25 Compositions for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10527893A 1993-08-12 1993-08-12
US08/105,278 1993-08-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10527893A Continuation-In-Part 1993-08-12 1993-08-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/450,862 Continuation-In-Part US5908623A (en) 1993-08-12 1995-05-25 Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Publications (2)

Publication Number Publication Date
WO1995005452A2 WO1995005452A2 (fr) 1995-02-23
WO1995005452A3 true WO1995005452A3 (fr) 1995-03-30

Family

ID=22304946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009299 Ceased WO1995005452A2 (fr) 1993-08-12 1994-08-12 Compositions et procedes ameliores pour l'administration de molecuiles a activite biologique a l'aide de cellules modifiees genetiquement comprises dans des capsules biocompatibles immuno-isolatrices

Country Status (13)

Country Link
US (4) US5676943A (fr)
EP (2) EP1179350A3 (fr)
JP (3) JP4098355B2 (fr)
AT (1) ATE218893T1 (fr)
AU (2) AU7568094A (fr)
CA (1) CA2169292C (fr)
DE (1) DE69430824T2 (fr)
DK (1) DK0802800T3 (fr)
ES (1) ES2178654T3 (fr)
FI (1) FI960611A7 (fr)
NO (1) NO960547L (fr)
SG (1) SG48813A1 (fr)
WO (1) WO1995005452A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354899B2 (en) 1998-08-14 2008-04-08 The University Of British Columbia Methods of treating autoimmune diseases comprising administering CXCR4 antagonists
US9138461B2 (en) 2007-05-01 2015-09-22 Biogen Ma Inc. Compositions and methods for increasing vascularization
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
USD755986S1 (en) 2013-03-07 2016-05-10 Viacyte, Inc. Cell encapsulation device
US10400214B2 (en) 2008-12-23 2019-09-03 Boco Silicon Valley, Inc. Target populations of oligodendrocyte precursor cells and methods of making and using same

Families Citing this family (291)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
US5744327A (en) * 1990-02-20 1998-04-28 Board Of Regents, The University Of Texas System Methods for producing insulin in response to non-glucose secretagogues
US5792656A (en) * 1991-06-03 1998-08-11 Board Of Regents, The University Of Texas System Methods of preparing genetically engineered cells that produce insulin in response to glucose
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5908623A (en) * 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5795790A (en) * 1994-07-20 1998-08-18 Cytotherapeutics, Inc. Method for controlling proliferation and differentiation of cells encapsulated within bioartificial organs
EP0831883A1 (fr) * 1995-05-12 1998-04-01 The Rockefeller University Traitement de la maladie d'alzheimer par modulation des synapsines
IN181898B (fr) * 1995-06-07 1998-10-24 Cytotherapeutics Inc
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7364894B2 (en) * 1995-09-15 2008-04-29 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
AU7204996A (en) * 1995-10-02 1997-04-28 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
US5855613A (en) * 1995-10-13 1999-01-05 Islet Sheet Medical, Inc. Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6224912B1 (en) * 1996-04-03 2001-05-01 The Rogo Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US7297331B2 (en) * 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
US6210664B1 (en) * 1996-04-08 2001-04-03 New York University Medical Center Method for gene transfer to the central nervous system
AU2674097A (en) * 1996-04-17 1997-11-07 Cytotherapeutics, Inc. Method and device for delivery of apoptosis-inducing molecules
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6054142A (en) * 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6150164A (en) * 1996-09-30 2000-11-21 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
AU718500B2 (en) 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
WO1998054213A2 (fr) * 1997-05-30 1998-12-03 Amgen Inc. Recepteurs du facteur neurotrope
WO1998057663A1 (fr) 1997-06-17 1998-12-23 University Technology Corporation Transplantation neuronale utilisee pour traiter les affections neurologiques
WO1999000148A2 (fr) * 1997-06-30 1999-01-07 The Regents Of The University Of California Methode de traitement de lesions de la moelle epiniere chez un mammifere
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
ZA986077B (en) 1997-07-09 2000-01-10 Genentech Inc ErbB4 receptor-specific neuregulin related ligands and uses therefor.
US6071748A (en) 1997-07-16 2000-06-06 Ljl Biosystems, Inc. Light detection device
US6469311B1 (en) 1997-07-16 2002-10-22 Molecular Devices Corporation Detection device for light transmitted from a sensed volume
US6994856B1 (en) 1997-07-24 2006-02-07 Genentech, Inc. ErbB4 receptor-specific neuregulin related ligands and uses therefor
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6042909A (en) * 1997-09-03 2000-03-28 Circe Biomedical, Inc. Encapsulation device
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US6576476B1 (en) 1998-09-02 2003-06-10 Ljl Biosystems, Inc. Chemiluminescence detection method and device
US6992761B2 (en) 1997-09-20 2006-01-31 Molecular Devices Corporation Broad range light detection system
WO2000050877A1 (fr) 1999-02-23 2000-08-31 Ljl Biosystems, Inc. Dispositif de detection de lumiere a domaine de frequence
US6297018B1 (en) 1998-04-17 2001-10-02 Ljl Biosystems, Inc. Methods and apparatus for detecting nucleic acid polymorphisms
US6825921B1 (en) 1999-11-10 2004-11-30 Molecular Devices Corporation Multi-mode light detection system
US6326605B1 (en) 1998-02-20 2001-12-04 Ljl Biosystems, Inc. Broad range light detection system
US6982431B2 (en) 1998-08-31 2006-01-03 Molecular Devices Corporation Sample analysis systems
US6156729A (en) 1997-10-15 2000-12-05 California Institute Of Technology Leukemia inhibitory factor for use in modulating inflammation and pain
US6485901B1 (en) * 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
CA2305787A1 (fr) 2000-05-09 2001-11-09 The University Of British Columbia Traitement antagoniste cxcr4 de cellules hematopoietiques
JP2002506830A (ja) 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
WO1999057248A1 (fr) * 1998-04-30 1999-11-11 President And Fellows Of Harvard College Induction de regeneration neurale
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2000004927A1 (fr) * 1998-07-24 2000-02-03 Alleghney University Of The Health Sciences Immunogenes cellulaires allogeniques utiles comme vaccins contre le cancer
AU5223899A (en) 1998-07-27 2000-02-21 Ljl Biosystems, Inc. Apparatus and methods for spectroscopic measurements
AU5667599A (en) 1998-07-27 2000-02-21 Ljl Biosystems, Inc. Apparatus and methods for time-resolved spectroscopic measurements
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
CZ300877B6 (cs) * 1998-09-09 2009-09-02 Myelos Corporation Lécivo pro lécení neurodegenerativních nebo myelinizacních poruch a virový vektor
EP1112090A2 (fr) * 1998-09-09 2001-07-04 Myelos Corporation Procede pour stimuler l'activite du recepteur de la prosaposine
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US6156514A (en) * 1998-12-03 2000-12-05 Sunol Molecular Corporation Methods for making recombinant cells
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
AU773954B2 (en) * 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US6713293B1 (en) * 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
US6395299B1 (en) 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
WO2000058479A1 (fr) 1999-03-26 2000-10-05 Amgen Inc. Genes et polypeptides beta secretase
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
WO2001011011A2 (fr) 1999-08-05 2001-02-15 Mcl Llc Cellules souches adultes toutes-puissantes et procede d'isolement
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US6878543B1 (en) 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
RU2152800C1 (ru) * 1999-12-08 2000-07-20 Зыбин Дмитрий Владимирович Способ культивирования и модификации гетерогенных клеток млекопитающих
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US6458118B1 (en) 2000-02-23 2002-10-01 Medtronic, Inc. Drug delivery through microencapsulation
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
MXPA02012718A (es) * 2000-06-28 2003-10-06 Amgen Inc Moleculas semejantes a b7 y sus usos.
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
JP4236925B2 (ja) 2000-11-28 2009-03-11 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US6958158B2 (en) * 2001-05-11 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc. Immune modulation device for use in animals
US7789039B2 (en) * 2001-06-22 2010-09-07 Université Catholique de Louvain Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
EP1281767A3 (fr) * 2001-07-31 2003-05-28 Aladar A. Szalay Microbes et cellules lumineuses pour le diagnostic et le traitement des tumeurs
US7332330B2 (en) 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
DE10164039A1 (de) * 2001-12-28 2003-07-10 Nmi Univ Tuebingen Implantierbare Vorrichtung und deren Verwendung
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7442546B2 (en) * 2002-03-15 2008-10-28 The Regents Of The University Of Michigan Method of modulating inflammatory response
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
DK1458853T3 (da) 2002-05-16 2010-04-06 Absorber Ab Fremgangsmåde til donorspecifik krydsmatchning
EP1369491A1 (fr) * 2002-06-05 2003-12-10 Aladar A. Szalay Microorganismes et cellules luminescents pour le diagnostic et la thérapie de maladies asociées avec du tissu blessé ou inflammé
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
HUE025872T2 (en) * 2002-06-18 2016-05-30 Eisai R&D Man Co Ltd Primary, cultured adipocytes for gene therapy
US7328069B2 (en) * 2002-09-06 2008-02-05 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by electrical stimulation of and the delivery of drugs to the left and right pudendal nerves
US7427280B2 (en) 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
US7328068B2 (en) * 2003-03-31 2008-02-05 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by means of electrical stimulation of the pudendal and associated nerves, and the optional delivery of drugs in association therewith
US7369894B2 (en) * 2002-09-06 2008-05-06 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the sacral and/or pudendal nerves
US7276057B2 (en) * 2002-09-06 2007-10-02 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by drug delivery to the pudendal and sacral nerves
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
US20040230182A1 (en) * 2002-12-27 2004-11-18 Medtronic, Inc. Drug delivery through encapsulation
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
WO2004094592A2 (fr) 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Neublastine a conjugaison polymere glycosylee
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
EP1624936B1 (fr) 2003-05-16 2009-10-28 Universite Laval Modulation de chlorure du snc et ses utilisations
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
ATE420160T1 (de) * 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
EP1667516A4 (fr) 2003-08-29 2009-11-11 Inst Medical W & E Hall Procede de selection de modeles d'animaux parmi les animaux ayant ete soumis a la mutagenese, et utilisation de facteurs de transcription myb pour le criblage
BRPI0415563A (pt) 2003-10-20 2007-01-02 Nsgene As método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional
EP1701736A4 (fr) 2003-12-24 2008-05-07 Inst Medical W & E Hall Agents therapeutiques et utilisations
US20080286323A1 (en) * 2004-01-19 2008-11-20 Nsgene A/S Human Therapeutic Cells Secreting Nerve Growth Factor
US8467875B2 (en) 2004-02-12 2013-06-18 Medtronic, Inc. Stimulation of dorsal genital nerves to treat urologic dysfunctions
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
WO2005108981A1 (fr) 2004-05-12 2005-11-17 The Walter And Eliza Hall Institute Of Medical Research Procede d'isolement de cellules
US8309070B2 (en) 2004-05-17 2012-11-13 Regents Of The University Of Minnesota Use of umbilical cord blood stem cells to treat ischemic event
WO2006013462A2 (fr) * 2004-07-30 2006-02-09 Nsgene A/S Facteurs de croissance nsg28, nsg30, et nsg32
DK1786454T3 (da) 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
CA2577690C (fr) 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Repliement des proteines de la famille du facteur de croissance transformant beta
US20060099193A1 (en) * 2004-10-22 2006-05-11 Ikuko Sugaya Methods and materials for suppressing pain
JP2008533995A (ja) 2005-04-01 2008-08-28 エヌエスジーン・アクティーゼルスカブ ヒト不死化神経前駆細胞系
US20060253068A1 (en) * 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
JP5541861B2 (ja) 2005-04-29 2014-07-09 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 超分岐ポリマーおよびそれらの適用
JP2008540347A (ja) * 2005-05-03 2008-11-20 フェテリネールメディツィニシュ ウニベルジテート ウィーン 浸透性カプセル
US20060257368A1 (en) * 2005-05-03 2006-11-16 Clemson University Devices and methods for improved viability of cells
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (fr) * 2005-05-06 2006-11-16 Medtronic, Inc. Procedes et sequences permettant de supprimer l'expression du gene de huntington chez les primates
EP1883446B8 (fr) 2005-05-17 2017-11-15 Gloria Therapeutics Sarl Systeme de therapie implantable pour traiter un etre vivant avec un facteur actif
US20090169523A1 (en) 2005-06-13 2009-07-02 Catherine Verfaillie Hsc self-renewal
AU2006261599B2 (en) 2005-06-24 2011-10-06 The Walter & Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
US9133517B2 (en) * 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US8357666B2 (en) 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
EP1940471A1 (fr) * 2005-10-28 2008-07-09 NsGene A/S Véhicule implantable, biocompatible, immuno-isolatoire pour livraison de gdnf
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) * 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
AU2006315037C1 (en) 2005-11-18 2013-05-02 Ichnos Sciences SA Anti-alpha2 integrin antibodies and their uses
CA2635534C (fr) 2005-12-30 2014-07-29 Neurotech Usa Inc. Dispositif micronise d'administration de molecules biologiquement actives et procede d'utilisation
NZ570614A (en) 2006-01-23 2012-07-27 Athersys Inc Multipotent adult progenitor cell treatment of brain injuries and diseases
CN104027359A (zh) 2006-01-23 2014-09-10 阿特西斯公司 无附加的免疫抑制治疗的mapc治疗法
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
CN106434527A (zh) 2006-04-14 2017-02-22 安斯泰来再生医药协会 血管瘤集落形成细胞
US20070255333A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Neuromodulation therapy for perineal or dorsal branch of pudendal nerve
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
AU2007275764B2 (en) 2006-07-18 2013-11-14 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CA2666789C (fr) * 2006-10-18 2016-11-22 Yong Zhao Cellules souches de type embryonnaire derivees du sang peripherique d'un etre humain adulte et procedes d'utilisation associes
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US7819842B2 (en) * 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US20080171906A1 (en) * 2007-01-16 2008-07-17 Everaerts Frank J L Tissue performance via hydrolysis and cross-linking
US8545834B2 (en) * 2007-03-15 2013-10-01 The Mclean Hospital Corporation G-substrate for the treatment and prevention of parkinson's disease
CA2887752C (fr) 2007-04-03 2020-03-24 Vib Vzw Glycosylation de molecules
CA2698212A1 (fr) 2007-08-23 2009-02-26 Intrexon Corporation Procedes et compositions de diagnostic d'une maladie
WO2009029508A1 (fr) * 2007-08-28 2009-03-05 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute, Inc. Cathéter intracrânien et procédés d'utilisation
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
PT2592148T (pt) 2007-10-12 2018-11-12 Hoffmann La Roche Expressão proteica de múltiplos ácidos nucleicos
AU2009205886B2 (en) 2008-01-18 2015-08-27 Katholieke Universiteit Leuven Stem cell aggregates and methods for making and using
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
WO2009125332A1 (fr) * 2008-04-07 2009-10-15 Peter Bromley Procédé nouveau et sans danger pour une immunisation contre des agents de maladies infectieuses
KR20110019727A (ko) 2008-04-07 2011-02-28 뉴포텐셜, 인크. Ｒｎａ 간섭을 통한 다능 유전자의 유도에 의한 세포 재프로그래밍
CA3186451A1 (fr) 2008-05-06 2009-11-12 Astellas Institute For Regenerative Medicine Cellules formant des colonies hemangioblastiques et cellules hemangioblastiques non transplantables
US20110086424A1 (en) 2008-05-06 2011-04-14 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
WO2009140649A2 (fr) * 2008-05-16 2009-11-19 Mclean Hosptial Rab3b pour le traitement et la prévention de la maladie de parkinson
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
DK2195013T3 (da) 2008-07-24 2012-02-06 Nsgene As Terapeutisk anvendelse af en vækstfaktor, METRNL
US9540630B2 (en) * 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
AU2010206374B2 (en) 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
EP2389191A2 (fr) 2009-01-23 2011-11-30 NsGene A/S Expression des neuropeptides dans les cellules des mammiféres
WO2010111278A1 (fr) 2009-03-23 2010-09-30 The Texas A&M University System Compositions de cellules souches mésenchymateuses pour régénérer l'os
JP2012524544A (ja) * 2009-04-23 2012-10-18 ニューロテック ユーエスエー， インコーポレイテッド プロスタグランジンＦ２アルファ（ＰＧＦ２ａ）を産生する細胞系およびその使用
WO2010129503A1 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
BRPI0902039B8 (pt) 2009-06-09 2021-05-25 Anhanguera Educacional Ltda composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais
SG10201502330TA (en) 2009-08-03 2015-05-28 Univ Miami Method for in vivo expansion of t regulatory cells
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
JP2013507373A (ja) * 2009-10-08 2013-03-04 ニューロテック ユーエスエー， インコーポレイテッド 被包された細胞ベースの送達系におけるｐｅｄｆの使用
WO2011061629A2 (fr) 2009-11-19 2011-05-26 Oxyrane Uk Limited Souches de levures produisant des n-glycanes complexes de type mammifère
WO2011079232A1 (fr) * 2009-12-23 2011-06-30 Psivida Us, Inc. Dispositifs d'administration à libération prolongée
SG183498A1 (en) 2010-02-25 2012-09-27 Abt Holding Co Modulation of angiogenesis
DK2539436T3 (da) 2010-02-25 2021-10-18 Abt Holding Co Modulering af makrofagaktivering
CA2796055A1 (fr) 2010-04-15 2011-10-20 Amgen Inc. Proteines de liaison au recepteur de fgf humain et a ?-klotho
JP5988961B2 (ja) 2010-04-28 2016-09-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 心筋細胞を発生させるための方法
SG185526A1 (en) 2010-05-12 2012-12-28 Abt Holding Co Modulation of splenocytes in cell therapy
WO2011154941A2 (fr) 2010-06-07 2011-12-15 Beta-O2 Technologies Ltd. Barrière immunitaire multicouche pour cellules donneuses
WO2011159726A2 (fr) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogrammation de cellules pour leur conférer un nouveau destin
WO2012027494A1 (fr) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Réactifs bispécifiques de ciblage
US9475709B2 (en) 2010-08-25 2016-10-25 Lockheed Martin Corporation Perforated graphene deionization or desalination
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
CA2812872C (fr) 2010-09-29 2021-08-03 Oxyrane Uk Limited Demannosylation des n-glycanes phosphoryles
WO2012041328A1 (fr) 2010-10-01 2012-04-05 Nsgene A/S Traitement de l'allodynie, de l'hyperalgésie, de la douleur spontanée et de la douleur illusionnelle
US8815942B2 (en) 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2646468B1 (fr) 2010-12-01 2018-07-25 AlderBio Holdings LLC Compositions anti-ngf et leur utilisation
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
JP2014506119A (ja) 2010-12-02 2014-03-13 ニューロテック ユーエスエー， インコーポレイテッド 抗血管新生抗体足場および可溶性受容体を分泌する細胞株およびその使用
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
SG195302A1 (en) 2011-06-06 2013-12-30 Kineta One Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
JP6145667B2 (ja) 2011-09-05 2017-06-14 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛、及び幻痛の治療
EP3628326B1 (fr) 2012-03-15 2024-02-28 Oxyrane UK Limited Méthodes et substances permettant de traiter la maladie de pompe
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US9844757B2 (en) 2014-03-12 2017-12-19 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
CN104640579A (zh) 2012-05-30 2015-05-20 神经技术美国有限公司 冷冻保存的可植入细胞培养装置及其用途
EP2879682B1 (fr) 2012-08-01 2018-03-21 United Therapeutics Corporation Traitement de l'hypertension artérielle pulmonaire avec des cellules souches mésenchymateuses
ES2713988T3 (es) 2012-08-01 2019-05-24 United Therapeutics Corp Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina
US20140193410A1 (en) 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
EP2943069B1 (fr) 2013-01-09 2018-08-15 United Therapeutics Corporation Traitement d'une vasculopathie par la prostacycline et des cellules souches mésenchymateuses
WO2014136065A2 (fr) 2013-03-05 2014-09-12 Oxyrane Uk Limited Production de sulfatase de type i catalytiquement active
AU2014225352B2 (en) 2013-03-07 2017-02-09 Viacyte, Inc. 3-dimensional large capacity cell encapsulation device assembly
TW201504140A (zh) 2013-03-12 2015-02-01 Lockheed Corp 形成具有均勻孔尺寸之多孔石墨烯之方法
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
IL289870B2 (en) 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
AU2014266935B2 (en) 2013-04-30 2020-06-11 Katholieke Universiteit Leuven Cell therapy for myelodysplastic syndromes
JP6681826B2 (ja) 2013-05-31 2020-04-15 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション コノトキシンペプチド、医薬組成物およびそれらの使用
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
CA2922483A1 (fr) 2013-09-11 2015-03-19 Neurotech Usa, Inc. Cartouche therapeutique a cellules encapsulees
WO2015042580A1 (fr) 2013-09-23 2015-03-26 Biogen Idec Ma Inc. Compositions et méthodes de traitement d'une douleur neuropathique
CN105940479A (zh) 2014-01-31 2016-09-14 洛克希德马丁公司 使用宽离子场穿孔二维材料
CN106029596A (zh) 2014-01-31 2016-10-12 洛克希德马丁公司 采用多孔非牺牲性支撑层的二维材料形成复合结构的方法
JP2017534311A (ja) 2014-09-02 2017-11-24 ロッキード・マーチン・コーポレーション 二次元膜材料をベースとする血液透析膜および血液濾過膜、ならびにそれを用いた方法
US20170266354A1 (en) * 2014-09-04 2017-09-21 Kemijski Institut Cell-Based Device For Local Treatment With Therapeutic Protein
CA2986769A1 (fr) 2015-05-27 2016-12-01 Neurotech Usa, Inc. Utilisation de therapie par cellules encapsulees pour le traitement de troubles ophtalmiques
JP2018528144A (ja) 2015-08-05 2018-09-27 ロッキード・マーチン・コーポレーション グラフェン系材料の穿孔可能なシート
WO2017023377A1 (fr) 2015-08-06 2017-02-09 Lockheed Martin Corporation Modification par nanoparticules et perforation de graphène
JP6877419B2 (ja) 2015-10-27 2021-05-26 ザ ユニバーシティー オブ クイーンズランド 治療の方法およびそのために有用な剤
EP3442786A4 (fr) 2016-04-14 2020-03-18 Lockheed Martin Corporation Structures de membrane en deux dimensions ayant des passages d'écoulement
KR20180133430A (ko) 2016-04-14 2018-12-14 록히드 마틴 코포레이션 결함 형성 또는 힐링의 인 시츄 모니터링 및 제어를 위한 방법
EP3442739A4 (fr) 2016-04-14 2020-03-04 Lockheed Martin Corporation Procédé de traitement de feuilles de graphène pour un transfert à grande échelle à l'aide d'un procédé à flottaison libre
WO2017180134A1 (fr) 2016-04-14 2017-10-19 Lockheed Martin Corporation Procédés pour l'utilisation in vivo et in vitro de graphène et d'autres matériaux bidimensionnels
EP3442697A4 (fr) 2016-04-14 2020-03-18 Lockheed Martin Corporation Atténuation interfaciale sélective des défauts du graphène
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
EP3272877A1 (fr) 2016-07-18 2018-01-24 ETH Zurich Cellules mimétiques de lymphocyte b
SG11201811763SA (en) 2016-07-18 2019-02-27 Eth Zuerich B-cell-mimetic cells
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
EP3534917B1 (fr) 2016-10-24 2022-08-24 United Therapeutics Corporation Amélioration de propriétés immunomodulatrices des csm par le tréprostinil
CA3042495A1 (fr) 2016-11-10 2018-05-17 Viacyte, Inc. Cellules d'endoderme pancreatique pdx1 dans des dispositifs d'administration de cellules et procedes associes
JP7021245B2 (ja) 2017-03-10 2022-02-16 エフ．ホフマン－ラ ロシュ アーゲー 多重特異性抗体を生産するための方法
US11304893B2 (en) 2017-07-24 2022-04-19 California Institute Of Technology Low power, chemically amplified, electrically removable barrier
EP3656851A1 (fr) 2018-11-23 2020-05-27 Technische Universität Dresden Lignées cellulaires d'alimentation artificielles positives au hla pour cellules nk et leurs utilisations
CA3134103A1 (fr) 2019-03-19 2020-09-24 Figene, Llc Traitement de la dependance aux opioides faisant appel a des fibroblastes et a des produits correspondants
PH12022551022A1 (en) 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
WO2022011081A1 (fr) 2020-07-09 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lignées cellulaires qui produisent des protéines de rétinoschisine humaine et leurs utilisations
US11644756B2 (en) * 2020-08-07 2023-05-09 KLA Corp. 3D structure inspection or metrology using deep learning
US20230383261A1 (en) 2020-10-14 2023-11-30 Sana Biotechnology, Inc. Hepatocyte-like cells
IT202100006569A1 (it) 2021-03-18 2022-09-18 Hemera S R L Metodo per ottenere macrofagi rigenerativi educati dal tumore e loro uso nella medicina rigenerativa
JP2024537531A (ja) 2021-11-05 2024-10-10 株式会社ヘリオス 拡大培養したイヌ前駆細胞および関連する方法
CN116077817B (zh) * 2021-12-06 2025-08-26 清源泰硕(北京)医疗器械有限公司 一种用于局部放疗的凝胶制剂注射系统
US20250152324A1 (en) 2022-02-25 2025-05-15 Viacyte, Inc. Multilayer implantable cell encapsulation devices and methods thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0161640A2 (fr) * 1984-05-14 1985-11-21 Merck & Co. Inc. Cellules de souris enkystées et transformées avec l'ADN rétrovirus aviaire-hormone de croissance bovine et un procédé pour administrer la BGH in vivo
WO1989004655A1 (fr) * 1987-11-17 1989-06-01 Brown University Research Foundation Diffusion in vivo de neurotransmetteurs par des cellules encapsulees implantees
WO1991010425A1 (fr) * 1990-01-08 1991-07-25 Brown University Research Foundation Systemes d'extrusion de capsules de cellules
WO1992019195A1 (fr) * 1991-04-25 1992-11-12 Brown University Research Foundation Vehicule implantable immuno-isolateur et biocompatible servant a apporter des produits therapeutiques selectionnes
WO1993000439A1 (fr) * 1991-06-28 1993-01-07 Brown University Research Foundation Apport in vivo de facteurs actifs par implants cellulaires de co-culture
WO1993002635A1 (fr) * 1991-07-30 1993-02-18 Baxter International Inc. Implant foramine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
US3615024A (en) * 1968-08-26 1971-10-26 Amicon Corp High flow membrane
US4409331A (en) * 1979-03-28 1983-10-11 Damon Corporation Preparation of substances with encapsulated cells
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
NO163060C (no) * 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
JPS59501747A (ja) * 1982-09-29 1984-10-18 スピ−ルバ−グ　セオドア−　イ− カプセル封入された、治療物質産生性の遺伝子操作された生物
US4470461A (en) * 1982-09-30 1984-09-11 Phillips Petroleum Company Organic nitro compounds as cosurfactants in enhanced oil recovery processes
EP0127989A3 (fr) * 1983-06-01 1986-03-26 Connaught Laboratories Limited Micro-encapsulation de tissu vivant et de cellules
US4806355A (en) * 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4689293A (en) * 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4749620A (en) * 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
CA1215922A (fr) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation de cellules et de tissus vivants
GB8500121D0 (en) * 1985-01-03 1985-02-13 Connaught Lab Microencapsulation of living cells
US4868121A (en) * 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
US4902295A (en) * 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4753635A (en) * 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
US5026365A (en) * 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4942129A (en) * 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
EP0301777A1 (fr) * 1987-07-28 1989-02-01 Queen's University At Kingston Microencapsulation multiple à membrane
US5049493A (en) * 1987-10-23 1991-09-17 California Institute Of Technology Enhancement of cell growth by expression of a cloned hemoglobin gene
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
GB8809129D0 (en) * 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5002661A (en) * 1989-08-25 1991-03-26 W. R. Grace & Co.-Conn. Artificial pancreatic perfusion device
EP0502949A4 (en) * 1989-12-05 1993-02-24 Trancel Corporation Homologous guluronic acid alginate coating composition for in-vivo application and implantation and method of using same
WO1991009119A1 (fr) * 1989-12-13 1991-06-27 Trancel Corporation Microcapsules d'alginate ameliorees et procedes pour leur fabrication et leur utilisation
WO1991010470A1 (fr) * 1990-01-08 1991-07-25 Brown University Research Foundation Dispositifs et procedes d'apport ameliore de facteurs actifs
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5167762A (en) * 1991-01-02 1992-12-01 Micron Technology, Inc. Anisotropic etch method
WO1993015608A1 (fr) * 1992-02-14 1993-08-19 Regeneron Pharmaceuticals, Inc. Facteurs specifiques prevenant les lesions et la degenerescence retinales
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0161640A2 (fr) * 1984-05-14 1985-11-21 Merck & Co. Inc. Cellules de souris enkystées et transformées avec l'ADN rétrovirus aviaire-hormone de croissance bovine et un procédé pour administrer la BGH in vivo
WO1989004655A1 (fr) * 1987-11-17 1989-06-01 Brown University Research Foundation Diffusion in vivo de neurotransmetteurs par des cellules encapsulees implantees
WO1991010425A1 (fr) * 1990-01-08 1991-07-25 Brown University Research Foundation Systemes d'extrusion de capsules de cellules
WO1992019195A1 (fr) * 1991-04-25 1992-11-12 Brown University Research Foundation Vehicule implantable immuno-isolateur et biocompatible servant a apporter des produits therapeutiques selectionnes
WO1993000439A1 (fr) * 1991-06-28 1993-01-07 Brown University Research Foundation Apport in vivo de facteurs actifs par implants cellulaires de co-culture
WO1993002635A1 (fr) * 1991-07-30 1993-02-18 Baxter International Inc. Implant foramine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOFFMAN D. ET AL: "TRANSPLANTATION OF A POLYMER-ENCAPSULATED CELL LINE GENETICALLY ENGINEERED TO RELEASE NGF", EXP. NEUROL., vol. 122, no. 1, July 1993 (1993-07-01), pages 100 - 106 *
WINN, SHELLEY R. ET AL: "POLYMER-ENCAPSULATED CELLS GENETICALLY MODIFIED TO SECRETE HUMAN NERVE GROWTH FACTOR PROMOTE THE SURVIVAL OF AXOTOMIZED SEPTAL CHOLINERGIC NEURONS", PROC. NATL. ACAD. SCI. U.S.A., vol. 91, no. 6, March 1994 (1994-03-01), pages 2324 - 2328 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354899B2 (en) 1998-08-14 2008-04-08 The University Of British Columbia Methods of treating autoimmune diseases comprising administering CXCR4 antagonists
US9138461B2 (en) 2007-05-01 2015-09-22 Biogen Ma Inc. Compositions and methods for increasing vascularization
US10400214B2 (en) 2008-12-23 2019-09-03 Boco Silicon Valley, Inc. Target populations of oligodendrocyte precursor cells and methods of making and using same
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US9493577B2 (en) 2009-12-07 2016-11-15 Amgen Inc. Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
USD755986S1 (en) 2013-03-07 2016-05-10 Viacyte, Inc. Cell encapsulation device

Also Published As

Publication number Publication date
DE69430824T2 (de) 2003-01-23
JPH09508002A (ja) 1997-08-19
WO1995005452A2 (fr) 1995-02-23
NO960547L (no) 1996-04-12
ES2178654T3 (es) 2003-01-01
EP1179350A2 (fr) 2002-02-13
US5653975A (en) 1997-08-05
ATE218893T1 (de) 2002-06-15
EP1179350A3 (fr) 2003-01-02
US5639275A (en) 1997-06-17
NO960547D0 (no) 1996-02-12
JP4524230B2 (ja) 2010-08-11
JP2006063081A (ja) 2006-03-09
EP0802800A2 (fr) 1997-10-29
AU717663B2 (en) 2000-03-30
DK0802800T3 (da) 2002-10-07
JP4098355B2 (ja) 2008-06-11
SG48813A1 (en) 1998-05-18
FI960611A0 (fi) 1996-02-09
AU9718498A (en) 1999-03-04
CA2169292C (fr) 2010-11-23
CA2169292A1 (fr) 1995-02-23
FI960611L (fi) 1996-04-09
US5656481A (en) 1997-08-12
EP0802800B1 (fr) 2002-06-12
US5676943A (en) 1997-10-14
DE69430824D1 (de) 2002-07-18
JP2008133285A (ja) 2008-06-12
AU7568094A (en) 1995-03-14
FI960611A7 (fi) 1996-04-09

Similar Documents

Publication Publication Date Title
WO1995005452A3 (fr) Compositions et procedes ameliores pour l'administration de molecuiles a activite biologique a l'aide de cellules modifiees genetiquement comprises dans des capsules biocompatibles immuno-isolatrices
EP1283268A3 (fr) Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)
DE69334257D1 (de) Methode zur Einführung von genetischem Material in Zellen
WO1999046366A8 (fr) Utilisations de cellules souches humaines mesenchymateuses non autologues
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
WO2001024842A3 (fr) Matrices hybrides et melanges de matrices hybrides
WO2001055212A3 (fr) Administration de produits biologiques therapeutiques a partir de matrices tissulaires implantables
PT699686E (pt) Fragmentos de peptido insulinotropico do tipo glucagona biologicamente activos
EP0568537A4 (fr) Modification genetique de cellules endotheliales.
ATE79024T1 (de) Implantate zur abgabe biologisch aktiver makromolekuele.
IL135578A0 (en) Compositions and methods for treating lysosomal storage disease
Payen et al. Improvement of mouse β-thalassemia by electrotransfer of erythropoietin cDNA
Carofino et al. Gene therapy applications for fracture-healing
WO2003023000A3 (fr) Fragments d'adn lineaires destines a l'expression genetique
WO2001092497A3 (fr) Molecules de glucose-6-phosphatase humaines et leurs utilisations
AU8435698A (en) Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
WO1999009142A1 (fr) Encapsulation de cellules de tissus vivants dans une microsphere
WO2000030667A3 (fr) Compositions et methodes d'utilisation de lactadherine ou de ses variants
HU9202092D0 (en) An implantate composition containing biologically active protein, peptide or polypeptide
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
US20090110669A1 (en) Methods for improving cell line activity in immunoisolation devices
WO2003086290A3 (fr) Electro-traitement de produits utilises dans la liberation de medicaments et l'encapsulation cellulaire
WO2003018829A3 (fr) 6299, membre de la famille des carboxypeptidases a zinc humaines et utilisations associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 08451044

Country of ref document: US

Ref document number: 08450316

Country of ref document: US

Ref document number: 08449946

Country of ref document: US

Ref document number: 08449756

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2169292

Country of ref document: CA

Ref document number: 960611

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1994925921

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 271883

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994925921

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994925921

Country of ref document: EP